Brian T. Powl
Known title: Chief Commercial OfficerCIK: 0001934232
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| KURA | ▼ Sell | Open Market | 10,000 | $110K | 5/21/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 339 | $3K | 5/19/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 1,572 | $13K | 1/27/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 4,842 | $41K | 1/27/2026 | View on chart |
| KURA | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 8,887 | $99K | 11/14/2025 | View on chart |
| KURA | ▲ Buy | Grant | 48,900 | $0 | 11/13/2025 | View on chart |
| KURA | ▼ Sell | Open Market | 8,891 | $80K | 9/29/2025 | View on chart |
| KURA | ▲ Buy | Grant | 48,900 | $0 | 9/27/2025 | View on chart |
| FATE | ▼ Sell | Open Market | 3,854 | $19K | 7/5/2023 | View on chart |
| FATE | ▲ Buy | Grant | 45,000 | $0 | 6/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project
Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.